Intangible Assets (Details Narrative) - USD ($)		1 Months Ended			11 Months Ended	12 Months Ended
	Nov. 15, 2016	Jun. 30, 2017	Nov. 30, 2016	Jul. 31, 2016	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Jul. 21, 2017
Common stock, shares issued					10,521,728	10,521,728	8,977,138
Purchase price of reserve merger consideration						$ 375,000
Goodwill					$ 3,502,829	$ 3,502,829	3,558,076
Estimated lives of finite intangible assets						5 years
Fair value of the assets acquired						$ 620,000
Intangible asset					2,555,974	2,555,974
Accumulated amortization of intangible assets					500,092	500,092
Amortization						$ 450,903	$ 49,189
Chief Commercial Officer [Member]
Number of restricted shares of common stock		60,000
2014 Long-Term Incentive Plan [Member] | Chief Commercial Officer [Member]
Number of restricted shares of common stock						60,000
Maximum [Member]
Goodwill					3,500,000	$ 3,500,000
IthenaPharma Inc [Member]
Common stock, shares issued	5,839,283
Ownership percentage of issued and outstanding shares	65.00%
Warrants to purchase shares of common stock	30,000
Maximum percentage of subsequent to the merger	50.00%
Purchase price of reserve merger consideration						3,700,000
Estimated purchase allocation goodwill valuation					$ 1,238,000	$ 55,247
Novosom Verwaltungs GmbH [Member]
Common stock issued during period shares	150,000
Novosom Verwaltungs GmbH [Member] | July 2010 Asset Purchase Agreement [Member]
Common stock issued during period, value				$ 15,000
Novosom Verwaltungs GmbH [Member] | July 2016 License Agreement [Member]
Common stock issued during period shares			11,905
Common stock issued during period, value			$ 15,000
Symplmed Pharmaceuticals LLC [Member] | Purchase Agreement [Member]
Purchase consideration		$ 620,000
Payment to acquire business		300,000
Liabilities assumed		$ 320,000
Symplmed Technologies, LLC [Member]
Intangible asset								$ 75,000